Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

When to add a second blood pressure drug in septic shock? large trial seeks answers

NCT ID NCT06217562

Disease control Sponsor: Intermountain Health Care, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 04, 2026 · Updated 4 times

Summary

This study looks at the best time to add the drug vasopressin for people with septic shock—a life-threatening drop in blood pressure from infection. About 2,050 adults will be treated using either an earlier or later threshold for starting vasopressin. The goal is to see which approach reduces deaths within 28 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vasopressin (a drug that raises blood pressure)
What this could lead to
If successful, this could help doctors know the best time to add vasopressin to treat septic shock, potentially saving more lives.
What could go wrong
This is a late-stage trial but compares two common strategies, so the difference may be small. Results may not apply to all hospitals or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

3,959 people

The number who actually took part.

Started

Feb 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years 2. Admitted to a study hospital emergency department (ED) or inpatient care unit 3. Administration of vasopressor(s) for septic shock Exclusion Criteria: None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Septic shock are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes insipidus toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Septic shock

Contacts and locations

Locations

  • Alta View Hospital

    Sandy City, Utah, 84094, United States

  • American Fork Hospital

    American Fork, Utah, 84003, United States

  • Cassia Regional Hospital

    Burley, Idaho, 83318, United States

  • Cedar City Hospital

    Cedar City, Utah, 84721, United States

  • Intermountain Medical Center

    Murray, Utah, 84107, United States

  • LDS Hospital

    Salt Lake City, Utah, 84143, United States

  • Layton Hospital

    Layton, Utah, 84041, United States

  • Logan Regional Hospital

    Logan, Utah, 84341, United States

  • McKay-Dee Hospital

    Ogden, Utah, 84403, United States

  • Park City Hospital

    Park City, Utah, 84060, United States

  • Riverton Hospital

    Riverton, Utah, 84065, United States

  • St. George Regional Hospital

    St. George, Utah, 84790, United States

  • Utah Valley Hospital

    Provo, Utah, 84604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.